TG Therapeutics (NASDAQ:TGTX - Get Free Report) issued its quarterly earnings results on Monday. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01), Briefing.com reports. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter last year, the firm posted $0.73 earnings per share. The company's revenue was down 49.4% on a year-over-year basis.
TG Therapeutics Trading Up 6.2 %
TGTX traded up $1.50 on Tuesday, reaching $25.86. 3,955,272 shares of the company's stock were exchanged, compared to its average volume of 3,648,657. The company has a market cap of $4.00 billion, a price-to-earnings ratio of -258.00 and a beta of 2.19. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58. TG Therapeutics has a twelve month low of $9.81 and a twelve month high of $26.99. The company's 50 day moving average is $23.51 and its 200-day moving average is $20.17.
Analyst Ratings Changes
Several research firms recently commented on TGTX. TD Cowen began coverage on TG Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. HC Wainwright upped their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a research report on Tuesday. Finally, B. Riley upped their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, TG Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $37.67.
Read Our Latest Stock Report on TGTX
TG Therapeutics Company Profile
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Recommended Stories
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
